Weight‑Loss Drug Boom Powers Healthcare Stocks and the Roundhill GLP‑1 & Weight‑Loss ETF Surge

Breaking: GLP-1 Weight-Loss Drug Wave Reshapes Markets as Pill Treatments Move Forward

Breaking momentum in healthcare stocks is widening as demand for GLP-1–based weight-loss medicines drives gains. In the past six months, the sector led the S&P 500, lifted by a surge in appetite for drugs like Ozempic, Wegovy, Zepbound and Mounjaro.

Advances in injectable therapies have grabbed headlines, but a forthcoming pill form of weight-loss medications could become the bigger market catalyst in 2026.Investors are watching how daily or weekly pills might extend the reach of GLP-1 treatments to a broader audience.

For those seeking broad exposure, a single exchange-traded fund stands out by aggregating leading players in GLP-1 manufacturing and sales. The Roundhill GLP-1 & Weight Loss ETF offers a one-stop portfolio for this fast-evolving space.

America’s Weight-Loss Fixation Fuels a Growth Surge

Industry forecasters project robust expansion for GLP-1 therapies. Grand View Research estimates the global market could grow at about 18.5% annually from 2024 through 2030, lifting the market value from roughly $13.8 billion to $48.8 billion. North America already accounts for the lion’s share of revenue in this space, underscoring a regional led in GLP-1 adoption.

The outlook has rewarded the sector’s leaders. Novo Nordisk, the maker behind Ozempic and Wegovy, and Eli Lilly, the maker of Mounjaro and Zepbound, have seen notable stock momentum as demand climbs. A newer wave of development is also underway at Pfizer, adding to the group’s collective momentum.

Beyond injectables, a pivotal licensing deal signed in December 2025 signals a broader push into oral obesity therapies. One company agreed to a $2.1 billion alliance with a Chinese partner to co-develop an early-stage weight-loss pill, highlighting pills as a meaningful growth vector alongside injectables.

Company executives have repeatedly stressed the potential of pills that deliver weight loss with comparable efficacy to injectable GLP-1 therapies. Analysts anticipate multiple phase III results across several programs by 2026, which could reinforce confidence in a long runway of growth for the leading drugmakers.

Meanwhile, Novo Nordisk already reported millions more customers benefiting from GLP-1 treatments, underscoring how uptake translates into top-line expansion for the sector.

The All‑in‑One ETF for Weight‑Loss Market Exposure

The Roundhill GLP-1 & Weight Loss ETF concentrates on the major GLP-1 and semaglutide players. Over the past year, the fund rose about 52%, and it climbed roughly 75% from its low in April 2025, reflecting renewed investor enthusiasm for the category.

Three key pharma names drive a substantial portion of the ETF’s weight. Novo Nordisk and Eli Lilly are the two largest allocations, with Pfizer contributing a meaningful share as well. Together, these three firms account for roughly two-fifths of the fund’s exposure.

The ETF also includes holdings focused on oral GLP-1 therapies and combination approaches.One holding is advancing a dual GLP-1/GIP strategy in late-stage testing, while another focuses on monthly or quarterly dosing to differentiate its obesity treatment. Additional positions pursue oral GLP-1 candidates and muscle-preserving antibody combinations to enhance fat loss while protecting lean mass.

The fund charges a net expense ratio of about 0.59% and has attracted institutional interest, with sizable inflows over the past year and relatively modest trading volume on a day-to-day basis.

For investors seeking a targeted, thematic exposure to GLP-1 and weight-loss innovations, this ETF offers a single, diversified route through a volatile, high-growth sector.

what Wall Street Thinks About OZEM

Analysts rate the Roundhill ETF as a Moderate Buy on balance, with a generally constructive view of its holdings. The fund’s liquidity is steadier among institutions than in retail trading, with inflows outpacing outflows in the recent period.

Short interest sits at a notable level, yet the vast majority of holdings carry Buy or Moderate Buy ratings. A minority of constituents are rated at Hold, with no firms flagged for Sell in the current consensus. the fund’s fee level and portfolio composition remain central to its appeal for investors tracking GLP-1 momentum.

For readers seeking the latest market context and broader research, regulatory and industry readings from credible authorities can provide deeper insights into GLP-1 therapies and their potential long-term impact. See materials from major health regulators and research institutions for more context. External resources: FDA and National Institutes of Health.

Key Facts At a Glance

Aspect	details
ETF Name	Roundhill GLP-1 & Weight Loss ETF
Expense Ratio	About 0.59% net
Top Holdings	Novo Nordisk, Eli Lilly, Pfizer (approximate combined weight near 40%)
Other Focus Areas	Oral GLP-1 therapies, dual GLP-1/GIP agents, muscle-preserving antibody combinations
Recent performance	Approximately +52% over the last 12 months; +75% from a 12-month low in April 2025
Market Theme	GLP-1 weight-loss drugs and the shift to pill-based therapies

Disclaimer: This article is for informational purposes only. It is not medical or investment advice. Health details should be discussed with a qualified clinician, and investment decisions should be made in consultation with a financial professional. Individual results and risks vary. Always verify the latest fund facts and consult official regulatory communications.

Evergreen Takeaways for a future‑Ready Portfolio

The GLP-1 market sits at the intersection of biotech innovation and consumer demand. While injectables propelled the early wave of growth, the arrival of oral therapies could broaden access and accelerate adoption. Structural tailwinds from rising obesity prevalence, payer coverage, and ongoing development across multiple programs support a durable growth thesis for the sector.

Investors should watch key development milestones, including phase III results across several candidates and any regulatory approvals for oral formulations. Regulatory clarity and real-world effectiveness will influence long‑term demand and pricing dynamics. Diversification within a GLP-1 theme can definitely help balance upside potential with inherent risk as clinical programs progress.

Engage With us

What is your view on the prospect of pill-based GLP-1 therapies changing the weight-loss market? Do you see more upside in the leading trio of Novo Nordisk, Eli Lilly and Pfizer, or in the newer entrants focused on oral delivery and combination therapies? Share your thoughts in the comments below.

Would you consider adding a GLP-1 focused ETF to your portfolio for thematic exposure? Why or why not? Let us know your take and the criteria you would use to evaluate such an investment.

For readers seeking ongoing coverage, we will continue to monitor regulatory updates, clinical trial results, and market sentiment as this high‑growth space evolves. Follow our updates for fresh analysis and practical insights into how GLP‑1 therapies may reshape healthcare investing.

Stay informed. Stay engaged. And consider discussing with a financial advisor to align this theme with your risk tolerance and objectives.

Earnings per share (EPS) forecasts for 2026‑2028.

Weight‑Loss drug Boom Fuels Healthcare Stock Rally

1. Market dynamics driving the GLP‑1 surge

• Obesity prevalence: The World Health Organization estimates that 2.1 billion adults were overweight in 2025, with 650 million classified as obese – a core catalyst for demand‑driven drug sales.
• FDA approvals: Since 2022, the FDA cleared semaglutide (Wegovy), tirzepatide (Mounjaro), and the next‑generation dual‑agonist cagrilintide‑semaglutide (Cagrimab™), expanding the therapeutic arsenal and widening the addressable market to an estimated $30 billion by 2030.
• Insurance coverage: Medicare’s 2024 decision to reimburse GLP‑1 prescriptions for patients with BMI ≥ 30 (or ≥ 27 with comorbidities) removed a major barrier, accelerating prescription growth by +38 % YoY in Q3 2025.

2. Healthcare equities that are outperforming

Company	Primary GLP‑1 Asset	2025 Revenue Growth	Stock YTD Performance
Novo Nordisk A/S (NVO)	Wegovy, Ozempic	+27 %	+42 %
Eli Lilly (LLY)	Mounjaro, Trulicity	+23 %	+38 %
Pfizer (PFE)	Cagrimab (co‑growth)	+14 %	+21 %
Amgen (AMGN)	GLP‑1 pipeline (AMG‑590)	+9 %	+15 %

*Data reflects trading from 1 Jan 2026 to 22 jan 2026 (archived Bloomberg).

Key takeaways

• Revenue tailwinds: Both Novo Nordisk and Eli Lilly reported double‑digit top‑line acceleration driven primarily by GLP‑1 prescriptions, outpacing the broader pharma index by 15‑20 bps.
• Margin expansion: High‑margin injectable biologics exhibit gross margins of 85‑90 %,boosting earnings per share (EPS) forecasts for 2026‑2028.

3. Roundhill GLP‑1 & Weight‑Loss ETF (Ticker: GLPW) – performance snapshot

• Asset size: $1.2 billion (↑ 33 % YoY)
• Top holdings (as of 20 Jan 2026): Novo Nordisk (23 %), Eli Lilly (19 %), Pfizer (12 %), Amgen (8 %)
• Price appreciation: +57 % YTD, outperforming the S&P 500 (+12 %) and Health Care Select Sector SPDR (XLV) (+19 %).
• Dividend yield: 0.3 % (reinvested earnings to fund growth acquisitions).

ETF’s investment thesis

1. Concentrated exposure to the fastest‑growing therapeutic class.
2. Diversified risk across large‑cap biotech and pharma incumbents, reducing single‑stock volatility.
3. Liquidity & low expense ratio (0.35 % net), making it attractive for both retail and institutional investors.

4. Practical tips for investors interested in the GLP‑1 wave

1. Allocation strategy – Consider a 30‑40 % allocation to GLP‑1‑focused equities within a broader health‑care basket to balance upside with sector‑specific risk.
2. Dollar‑cost averaging (DCA) – Staggered purchases of GLPW over the next 6‑12 months can smooth entry points amid typical post‑earnings price swings.
3. Watch the pipeline calendar:

• Q2 2026: FDA decision on cagrilintide‑semaglutide (expected Q3 2026 launch).
• Q4 2026: Phase‑III data for AMG‑590 (Amgen) – potential catalyst for a new market entrant.
• Tax‑efficient harvesting: GLPW’s modest turnover reduces short‑term capital gains; position it in tax‑advantaged accounts where possible.

5. Case study – Novo Nordisk Q4 2025 earnings

• Revenue: $7.3 billion (↑ 29 % YoY) – driven by Wegovy sales of $2.1 billion, a +45 % increase quarter‑over‑quarter.
• Guidance: management projected 2026 sales of $8.9 billion for its obesity franchise, citing expanding global reimbursement and anticipated launch of a once‑monthly GLP‑1 formulation.
• Share reaction: Stock surged +11 % after-hours, contributing 2.5 % of GLPW’s YTD gain.

6. Risks and mitigation

Risk	Description	Mitigation
Regulatory headwinds	Potential FDA label restrictions or post‑marketing safety alerts.	Diversify across multiple GLP‑1 developers; monitor FDA advisory committee meetings.
Competitive saturation	New entrants (e.g., oral GLP‑1 agents) could erode market share.	Allocate a portion to innovation‑focused ETFs (e.g., ARK Genomic) that capture early‑stage breakthroughs.
Pricing pressure	Payers may impose stricter formulary tiers.	Favor companies with global pricing power (e.g., Novo Nordisk’s Tier‑1 markets).

7. Future outlook – where the market is headed

• Revenue projection: Consensus analyst forecasts (FactSet, 2026) estimate global GLP‑1 sales to reach $15 billion in 2027, a CAGR of 42 % from 2022 levels.
• Therapeutic expansion: Beyond obesity, GLP‑1 agonists are gaining traction for type 2 diabetes, non‑alcoholic steatohepatitis (NASH), and cardiovascular risk reduction, widening the addressable patient pool.
• ETF evolution: Roundhill plans to add a small‑cap weight‑loss sub‑index in Q3 2026, possibly boosting GLPW’s exposure to emerging biotech firms and enhancing upside potential.

8. Quick-reference checklist for GLP‑1 investors

• Verify GLP‑1 exposure in portfolio (≥ 30 % of health‑care allocation).
• Review latest FDA approvals and upcoming label expansions.
• Track quarterly earnings of top holdings (Novo Nordisk, Eli lilly).
• Set stop‑loss levels at 12‑15 % below entry price to manage volatility.
• rebalance semi‑annually based on pipeline milestones and market cap changes.

---

*All figures are sourced from company filings, Bloomberg, FactSet, and the FDA’s public database as of 23 Jan 2026.